Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 8 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 9 |
Unknown | 2 |
Hormone | 1 |
Target |
Mechanism GCGR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Mar 2021 |
Target |
Mechanism GLP-2R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GLP-1R agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Sep 2023 |
Sponsor / Collaborator ![]() [+1] |
Start Date09 May 2023 |
Sponsor / Collaborator |
Start Date27 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Dasiglucagon ( GCGR ) | Hypoglycemia More | Approved |
Glepaglutide ( GLP-2R ) | Short Bowel Syndrome More | NDA/BLA |
Dapiglutide ( GLP-1R x GLP-2R ) | Obesity More | Phase 2 |
Elsiglutide ( GLP-2R ) | Diarrhea More | Phase 2 |
Petrelintide ( Amylin receptor ) | Overweight More | Phase 1 |